- CEO
- Takashi Nakamura
- Full Time Employees
- 6,247
- Sector
- Retail trade
- Industry
- Drugstore chains
- Address
- Shiroyama Trust Tower Tokyo TY Japan 105-8452
- IPO Date
- Apr 21, 2006
- Business
- Qol Holdings Co., Ltd. (3034.T) is a Japan-based holding company primarily engaged in the pharmacy, BPO contracting, and pharmaceutical manufacturing businesses; it operates through three main segments including the management of dispensing pharmacies under the QOL Pharmacy brand, contract sales organization (CSO) services featuring contract medical representative (CMR) dispatches, contract research organization (CRO) support for clinical trials in ethical drugs, OTC drugs, functional foods, and healthcare products with strengths in food, dermatology, and ophthalmology fields, medical professional referral dispatch for pharmacists, nurses, registered sellers, and dietitians, medical-related publishing of books and magazines for professionals and patients, and manufacturing and sales of authorized generic (AG) drugs and other pharmaceuticals through subsidiaries such as DAIICHI SANKYO ESPHA CO., LTD. and Fujinaga Pharm Co., Ltd. including products like Zonisamide OD Tablets (TRERIEF OD Tablets), Phenobal, Hydantol, Fujinaga lithium carbonate, and SARS-CoV-2 antigen test kits (Tegaruna stick SARS-CoV-2 Ag); the Pharmacy Business emphasizes one-on-one pharmacies aligned with specific medical institutions for efficient operations and high-quality medication guidance, healthcare pharmacies via alliances with Lawson, BIC CAMERA, MUJI, and train stations, home medical care, community-based integrated care with visiting services and mobile sales of OTC products, certified community medical coordination pharmacies, specialized pharmacies for cancer and advanced conditions, health support functions with nutrition advice and fairs, and digital enhancements like Qol Okusuribin LINE-based prescription ordering with same-day delivery and medication records sync, plus drone delivery experiments and the November 2024 launch of Qol Dokodemo Pharmacy online service in partnership with KDDI Corporation. Founded on October 4, 1992 and headquartered at 37th Floor Shiroyama Trust Tower, 4-3-1 Toranomon, Minato-ku, Tokyo, the company lists on the Tokyo Stock Exchange Prime Market and employs approximately 5,856 regular and 2,252 temporary staff as of March 31, 2024, with operations spanning all Japanese regions from Hokkaido to Okinawa including 953 stores (931 dispensing pharmacies) concentrated in Kanto (42%), Kansai (15%), and Koshinetsu (14%) as of September 2024. Recent developments include the October 2018 transition to a holding company structure from Qol Co., Ltd., aggressive M&A expansions such as acquiring Yokohama Yakugyo Service Co., Ltd. and Yokohama Pharmaceutical Services in 2025, Dyna Co., Ltd. (18 stores in Yamanashi), Gyotoku Pharmacy Co., Ltd., and Bottom Heart Co., Ltd. (365-day pharmacies near JR Yamanote Line), ClinCloud via subsidiary APO PLUS STATION for EDC solutions and CRO data management strengthening in October 2025, additional 21% stake in DAIICHI SANKYO ESPHA in April 2024 raising ownership to 51% for consolidation (planning full ownership via further purchases funded by borrowings totaling ¥25.0 billion), launch of three new AG products at DAIICHI SANKYO ESPHA in December 2024 alongside strong June 2024 Zonisamide sales, segment reclassification in FY3/25 to highlight Pharmaceutical Manufacturing separately, and medium-term targets of ¥300 billion net sales and ¥24 billion operating income by FY3/27 through 4%+ annual pharmacy growth via 30-40 M&A stores yearly, 10% BPO organic expansion on personnel demand, and ¥100 billion sales/¥12 billion operating income at DAIICHI SANKYO ESPHA via 3-4 annual AG launches, cost reforms, and DX productivity gains.